Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic prostate cancer
Abstract Metastatic prostate cancer (PCa) is not curable due to its ability to acquire therapy resistance. Theoretically, acquired therapy resistance can be driven by changes to previously sensitive cancer cells or their environment and/or by outgrowth of a subpopulation of cancer cells with primary...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Nature Portfolio
2024-12-01
|
| Ráidu: | npj Precision Oncology |
| Liŋkkat: | https://doi.org/10.1038/s41698-024-00773-w |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|